CTLA4 and hepatocellular carcinoma: However, as monotherapies, PD-1 inhibitors (e.g., pembrolizumab), PD-L1 inhibitors (e.g., atezolizumab), and CTLA-4 inhibitors (e.g., tremelimumab) have demonstrated only modest clinical efficacy in HCC (52–55).